Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 20:11:767697.
doi: 10.3389/fonc.2021.767697. eCollection 2021.

Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management

Abby R Templeton  1   2   3   4 , Penny L Jeffery  1   2   3   4 , Patrick B Thomas  1   2   3   4 , Mahasha P J Perera  1   2   3   4   5 , Gary Ng  2   6 , Alivia R Calabrese  1   2   3   4 , Clarissa Nicholls  1   2   3 , Nathan J Mackenzie  1   2   3   4 , Jack Wood  1   2   3 , Laura J Bray  2   7   8 , Ian Vela  1   2   3   4   5 , Erik W Thompson  1   2 , Elizabeth D Williams  1   2   3   4
Affiliations
Review

Patient-Derived Explants as a Precision Medicine Patient-Proximal Testing Platform Informing Cancer Management

Abby R Templeton et al. Front Oncol. .

Abstract

Precision medicine approaches that inform clinical management of individuals with cancer are progressively advancing. Patient-derived explants (PDEs) provide a patient-proximal ex vivo platform that can be used to assess sensitivity to standard of care (SOC) therapies and novel agents. PDEs have several advantages as a patient-proximal model compared to current preclinical models, as they maintain the phenotype and microenvironment of the individual tumor. However, the longevity of PDEs is not compatible with the timeframe required to incorporate candidate therapeutic options identified by whole exome sequencing (WES) of the patient's tumor. This review investigates how PDE longevity varies across tumor streams and how this is influenced by tissue preparation. Improving longevity of PDEs will enable individualized therapeutics testing, and thus contribute to improving outcomes for people with cancer.

Keywords: cancer; ex vivo; patient-derived explants; precision medicine; whole exome sequencing.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Jackson SE, Chester JD. Personalised Cancer Medicine. Int J Cancer (2015) 137(2):262–6. doi: 10.1002/ijc.28940 - DOI - PubMed
    1. Arnedos M, Vielh P, Soria J-C, Andre F. The Genetic Complexity of Common Cancers and the Promise of Personalized Medicine: Is There Any Hope? J Pathol (2014) 232(2):274–82. doi: 10.1002/path.4276 - DOI - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell (2011) 144(5):646–74. doi: 10.1016/j.cell.2011.02.013 - DOI - PubMed
    1. Bleijs M, van de Wetering M, Clevers H, Drost J. Xenograft and Organoid Model Systems in Cancer Research. EMBO J (2019) 38(15):e101654. doi: 10.15252/embj.2019101654 - DOI - PMC - PubMed
    1. Senft D, Leiserson MDM, Ruppin E, Ronai ZA. Precision Oncology: The Road Ahead. Trends Mol Med (2017) 23(10):874–98. doi: 10.1016/j.molmed.2017.08.003 - DOI - PMC - PubMed

LinkOut - more resources